MedTrace Logo

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

NCT02057640 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-12-11

Study results available
· View outcomes & findings →

Summary

This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma. This study will also look at the response and clinical benefit of the treatment and the progression-free survival and overall survival of study participants.

Conditions

Interventions

DRUG

Panobinostat

20mg, on day 1, 3, 5, 15, 17, 19, 28

DRUG

Dexamethasone

20mg, on day 1, 2, 8, 9, 15, 16, 28

DRUG

MLN9708

4mg on day 1, 8, 15, 28

Sponsors & Collaborators

  • Jason Valent

    lead OTHER

Principal Investigators

  • Jason Valent, MD · Case Comprehensive Cancer Center

  • Ehsan Malek, MD · Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-22
Primary Completion
2018-05-15
Completion
2018-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057640 on ClinicalTrials.gov